Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK centre for asbestos-related medtech R&D "progressing rapidly"

This article was originally published in Clinica

Executive Summary

The establishment in the UK of a National Centre for Asbestos-Related Diseases (NCARD) is "moving forward" and "progressing quite rapidly", MPs have been told. The issue was on the agenda of yesterday evening's meeting of the Asbestos Sub-Committee of the All-Party Parliamentary Group on Occupational Safety and Health. Chairman Michael Clapham MP told the committee that a leading UK consultant acting as adviser to the committee had held a number of meetings on the project and "is quite satisfied with the progress being made".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel